20
24
Annual
Report

Creating the future in peptides

Editorial

“In 2024, we achieved substantial improvements in profitability and cash flow. With the progress made, we are positioned for strong growth.”

Peter Wilden

Chairman
of the Board of Directors

Juan-José González

CEO

Highlights

Revenue

€m336.8

+5.1%

EBITDA

€m25.4

Margin +9.4 ppts

Operating cash flow

€m89.4

+145.0%